Non-Small Cell Lung Cancer - Pipeline Review, H2 2017

Date: December 13, 2017
Pages: 2678
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NA28E2E58C0EN
Leaflet:

Download PDF Leaflet

Non-Small Cell Lung Cancer - Pipeline Review, H2 2017
Non-Small Cell Lung Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H2 2017, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 47, 206, 192, 18, 167, 19 and 15 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 13, 14, 45 and 5 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Non-Small Cell Lung Cancer - Overview
Non-Small Cell Lung Cancer - Therapeutics Development
Non-Small Cell Lung Cancer - Therapeutics Assessment
Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development
Non-Small Cell Lung Cancer - Drug Profiles
Non-Small Cell Lung Cancer - Dormant Projects 2564
Non-Small Cell Lung Cancer - Discontinued Products 2586
Non-Small Cell Lung Cancer - Product Development Milestones 2595
Appendix 2606

LIST OF TABLES

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.13), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.14), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.15), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.16), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.17), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.18), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.19), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.20), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.21), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Products under Development by Companies, H2 2017 (Contd.13), H2 2017
Products under Development by Companies, H2 2017 (Contd.14), H2 2017
Products under Development by Companies, H2 2017 (Contd.15), H2 2017
Products under Development by Companies, H2 2017 (Contd.16), H2 2017
Products under Development by Companies, H2 2017 (Contd.17), H2 2017
Products under Development by Companies, H2 2017 (Contd.18), H2 2017
Products under Development by Companies, H2 2017 (Contd.19), H2 2017
Products under Development by Companies, H2 2017 (Contd.20), H2 2017
Products under Development by Companies, H2 2017 (Contd.21), H2 2017
Products under Development by Companies, H2 2017 (Contd.22), H2 2017
Products under Development by Companies, H2 2017 (Contd.23), H2 2017
Products under Development by Companies, H2 2017 (Contd.24), H2 2017
Products under Development by Companies, H2 2017 (Contd.25), H2 2017
Products under Development by Companies, H2 2017 (Contd.26), H2 2017
Products under Development by Companies, H2 2017 (Contd.27), H2 2017
Products under Development by Companies, H2 2017 (Contd.28), H2 2017
Products under Development by Companies, H2 2017 (Contd.29), H2 2017
Products under Development by Companies, H2 2017 (Contd.30), H2 2017
Products under Development by Companies, H2 2017 (Contd.31), H2 2017
Products under Development by Companies, H2 2017 (Contd.32), H2 2017
Products under Development by Companies, H2 2017 (Contd.33), H2 2017
Products under Development by Companies, H2 2017 (Contd.34), H2 2017
Products under Development by Companies, H2 2017 (Contd.35), H2 2017
Products under Development by Companies, H2 2017 (Contd.36), H2 2017
Products under Development by Companies, H2 2017 (Contd.37), H2 2017
Products under Development by Companies, H2 2017 (Contd.38), H2 2017
Products under Development by Companies, H2 2017 (Contd.39), H2 2017
Products under Development by Companies, H2 2017 (Contd.40), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.8), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.9), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.10), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.11), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.12), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.13), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.14), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.8), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.9), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.10), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.11), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.12), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.13), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H2 2017
Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2017
Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Adamed Sp z oo, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by ADC Therapeutics Sarl, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Aduro BioTech Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Advantagene Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Advaxis Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Agenus Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Altimmune Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corp, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Amgen Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by AndroScience Corp, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Apexigen Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Argos Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by ARMO Biosciences Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by ArQule Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Asana BioSciences LLC, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Atreca Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Aurobindo Pharma Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Batu Biologics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H2 2017
Non-Small Cell Lung Cancer - Pipeline by BeiGene Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by BerGenBio ASA, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Beta Pharma Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Bicycle Therapeutics Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Biocad, H2 2017
Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Biocon Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by BioLineRx Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Bionovis SA, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corp, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by BrightPath Biotherapeutics Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Cadila Healthcare Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Calithera Biosciences Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by CanBas Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Cantargia AB, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Celgene Corp, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Cell Medica Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Cellmid Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Checkpoint Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Cielo Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Cleave Biosciences Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Cleveland BioLabs Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Coherus BioSciences Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Corcept Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Cortice Biosciences Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H2 2017
Non-Small Cell Lung Cancer - Pipeline by CytomX Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Cytori Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by DAE HWA Pharmaceutical Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Debiopharm International SA, H2 2017
Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by DelMar Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Denovo Biopharma LLC, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Domainex Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Dynavax Technologies Corp, H2 2017
Non-Small Cell Lung Cancer - Pipeline by eFFECTOR Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Eisai Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Co, H2 2017
Non-Small Cell Lung Cancer - Pipeline by EnGeneIC Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by EntreChem SL, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Enumeral Biomedical Holdings Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Enzene Biosciences Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by EpiThany Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Epizyme Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Eudendron Srl, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Evotec AG, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Exelixis Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by F-star Biotechnology Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by FibroStatin SL, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Formosa Laboratories Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Fountain Biopharma Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Fujifilm Holdings Corporation, H2 2017
Non-Small Cell Lung Cancer - Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by G1 Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Galectin Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Genelux Corp, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Genentech Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Genmab A/S, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Genocea Biosciences Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Genosco Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Genzyme Corp, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Gilead Sciences Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by GlycaNova Norway AS, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Glycotope GmbH, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Golden Biotechnology Corp, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Gradalis Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Grunenthal GmbH, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Heat Biologics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Helix BioPharma Corp, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Hemispherx Biopharma Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Heptares Therapeutics Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by HitGen LTD, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by iCeutica Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Ideaya Biosciences Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Ignyta Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Immatics Biotechnologies GmbH, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Immune Design Corp, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by ImmunGene Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Immunocore Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by ImmunoGen Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Immunomedics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Imugene Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Incyte Corp, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Infinity Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Inflection Biosciences Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Innovent Biologics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Invectys SA, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Inventiva, H2 2017
Non-Small Cell Lung Cancer - Pipeline by IO Biotech ApS, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Io Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by JHL Biotech Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Jounce Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Juno Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Kadmon Corp LLC, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Kite Pharma Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Kura Oncology Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Laboratoires Pierre Fabre SA, H2 2017
Non-Small Cell Lung Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Leap Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Lidds AB, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Loxo Oncology Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Luye Pharma Group Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Lycera Corp, H2 2017
Non-Small Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by MacroGenics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017
Non-Small Cell Lung Cancer - Pipeline by MallInckrodt Plc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Mebiopharm Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by MedImmune LLC, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Merck & Co Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Merck KGaA, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Mersana Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Merus NV, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Microlin Bio Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Mirati Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Moderna Therapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Molecular Partners AG, H2 2017
Non-Small Cell Lung Cancer - Pipeline by MolMed SpA, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Morphotek Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Multimmune GmbH, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Mundipharma International Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Mycenax Biotech Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by NanoCarrier Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by NantKwest Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Natco Pharma Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Nektar Therapeutics, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Neumedicines Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by NewLink Genetics Corp, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Oncobiologics Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Oncolys BioPharma Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Oncolytics Biotech Inc, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Onxeo SA, H2 2017
Non-Small Cell Lung Cancer - Pipeline by Optimum Therapeutics LLC, H2 2017

LIST OF FIGURES

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2017 86
Number of Products under Development by Companies, H2 2017 87
Number of Products under Development by Universities/Institutes, H2 2017 110
Number of Products by Top 10 Targets, H2 2017 159
Number of Products by Stage and Top 10 Targets, H2 2017 159
Number of Products by Top 10 Mechanism of Actions, H2 2017 175
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 175
Number of Products by Top 10 Routes of Administration, H2 2017 190
Number of Products by Stage and Top 10 Routes of Administration, H2 2017 190
Number of Products by Top 10 Molecule Types, H2 2017 192
Number of Products by Stage and Top 10 Molecule Types, H2 2017 192

COMPANIES MENTIONED

3-V Biosciences Inc
3SBio Inc
4SC AG
AbbVie Inc
Ability Pharmaceuticals SL
ACEA Biosciences Inc
Adamed Sp z oo
Adaptimmune Therapeutics Plc
ADC Therapeutics Sarl
Aduro BioTech Inc
Advantagene Inc
Advaxis Inc
Advenchen Laboratories LLC
Agenus Inc
Allist Shanghai Pharmaceutical Technology Co Ltd
Altimmune Inc
Altor BioScience Corp
Amgen Inc
Andarix Pharmaceuticals Inc
AndroScience Corp
Apexigen Inc
Aptose Biosciences Inc
Argos Therapeutics Inc
Ariad Pharmaceuticals Inc
ARMO Biosciences Inc
ArQule Inc
Array BioPharma Inc
Asana BioSciences LLC
Ascentage Pharma Group Corp Ltd
Astellas Pharma Inc
Asterias Biotherapeutics Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atreca Inc
Aurigene Discovery Technologies Ltd
Aurobindo Pharma Ltd
AVEO Pharmaceuticals Inc
Basilea Pharmaceutica Ltd
Batu Biologics Inc
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Beijing Hanmi Pharmaceutical Co Ltd
BerGenBio ASA
Beta Pharma Inc
Betta Pharmaceuticals Co Ltd
BeyondSpring Pharmaceuticals Inc
Bicycle Therapeutics Ltd
Bio-Cancer Treatment International Ltd
Biocad
BioCancell Ltd
Biocon Ltd
Biohaven Pharmaceutical Holding Company Ltd
BioLineRx Ltd
Bionovis SA
Biothera Pharmaceutical Inc
Blueprint Medicines Corp
Boehringer Ingelheim GmbH
Boston Biomedical Inc
BrightPath Biotherapeutics Co Ltd
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Calithera Biosciences Inc
CanBas Co Ltd
Cantargia AB
Cascadian Therapeutics Inc
CASI Pharmaceuticals Inc
CBT Pharmaceuticals Inc
Celgene Corp
Cell Medica Ltd
Celldex Therapeutics Inc
Cellmid Ltd
Cellular Biomedicine Group Inc
Checkpoint Therapeutics Inc
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co Ltd
Cielo Therapeutics Inc
Cleave Biosciences Inc
Cleveland BioLabs Inc
Coherus BioSciences Inc
Corcept Therapeutics Inc
Cortice Biosciences Inc
Corvus Pharmaceuticals Inc
Critical Outcome Technologies Inc
CSPC Pharmaceutical Group Limited
CytomX Therapeutics Inc
Cytori Therapeutics Inc
DAE HWA Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
DanDrit Biotech A/S
Debiopharm International SA
DEKK-TEC Inc
DelMar Pharmaceuticals Inc
Denovo Biopharma LLC
Domainex Ltd
Double Bond Pharmaceutical International AB
Dr. Reddy's Laboratories Ltd
Dynavax Technologies Corp
eFFECTOR Therapeutics Inc
Eisai Co Ltd
Eleison Pharmaceuticals LLC
Eli Lilly and Co
EnGeneIC Ltd
EntreChem SL
Enumeral Biomedical Holdings Inc
Enzene Biosciences Ltd
EpiThany Inc
Epizyme Inc
Eudendron Srl
Evotec AG
Exelixis Inc
F-star Biotechnology Ltd
F. Hoffmann-La Roche Ltd
FibroStatin SL
Five Prime Therapeutics Inc
Formosa Laboratories Inc
Fountain Biopharma Inc
Fujifilm Holdings Corporation
G&E Herbal Biotechnology Co Ltd
G1 Therapeutics Inc
Galectin Therapeutics Inc
Gene Techno Science Co Ltd
Genelux Corp
Genentech Inc
Genmab A/S
Genocea Biosciences Inc
Genor BioPharma Co Ltd
Genosco Inc
Genzyme Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
GlycaNova Norway AS
Glycotope GmbH
Golden Biotechnology Corp
Gradalis Inc
Grunenthal GmbH
Halozyme Therapeutics Inc
Hanmi Pharmaceuticals Co Ltd
Heat Biologics Inc
Helix BioPharma Corp
Hemispherx Biopharma Inc
Heptares Therapeutics Ltd
HitGen LTD
Horizon Pharma Plc
Hutchison MediPharma Ltd
iCeutica Inc
Ideaya Biosciences Inc
Ignyta Inc
Immatics Biotechnologies GmbH
Immune Design Corp
Immune Pharmaceuticals Inc
ImmunGene Inc
Immunocore Ltd
ImmunoGen Inc
Immunomedics Inc
Imugene Ltd
Incyte Corp
Infinity Pharmaceuticals Inc
Inflection Biosciences Ltd
Innovation Pharmaceuticals Inc
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Invectys SA
Inventiva
IO Biotech ApS
Io Therapeutics Inc
Iovance Biotherapeutics Inc
JHL Biotech Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Jounce Therapeutics Inc
Juno Therapeutics Inc
Kadmon Corp LLC
Karyopharm Therapeutics Inc
Kite Pharma Inc
Kura Oncology Inc
Kyowa Hakko Kirin Co Ltd
Laboratoires Pierre Fabre SA
LATITUDE Pharmaceuticals Inc
Leap Therapeutics Inc
Les Laboratoires Servier SAS
Lidds AB
Loxo Oncology Inc
Luye Pharma Group Ltd
Lycera Corp
MabVax Therapeutics Holdings Inc
MacroGenics Inc
Madrigal Pharmaceuticals Inc.
MallInckrodt Plc
Mebiopharm Co Ltd
MedImmune LLC
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Mersana Therapeutics Inc
Merus NV
Microlin Bio Inc
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Moderna Therapeutics Inc
Molecular Partners AG
MolMed SpA
Morphotek Inc
Multimmune GmbH
Mundipharma International Ltd
Mycenax Biotech Inc
NanoCarrier Co Ltd
NantKwest Inc
Natco Pharma Ltd
Nektar Therapeutics
Neumedicines Inc
NewLink Genetics Corp
Northwest Biotherapeutics Inc
Novartis AG
Oncobiologics Inc
Oncolys BioPharma Inc
Oncolytics Biotech Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
Optimum Therapeutics LLC
OSE Immunotherapeutics
Paranta Biosciences Ltd
Peptomyc SL
Peregrine Pharmaceuticals Inc
Pfizer Inc
Pharma Mar SA
Philogen SpA
Phosplatin Therapeutics LLC
Pique Therapeutics
Plexxikon Inc
Polaris Pharmaceuticals Inc
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
Purdue Pharma LP
Qilu Pharmaceutical Co Ltd
Qu Biologics Inc
Qurient Co Ltd
Rafael Pharmaceuticals Inc
RaQualia Pharma Inc
Reata Pharmaceuticals Inc
Recombio SL
Regeneron Pharmaceuticals Inc
Rexahn Pharmaceuticals Inc
Rgenix Inc
Richter Gedeon Nyrt
RS Research
Samyang Holdings Corp
Sanofi
Scancell Holdings Plc
SciClone Pharmaceuticals Inc
ScinoPharm Taiwan Ltd
Seattle Genetics Inc
Selvita SA
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Pharmaceutical Co Ltd
Shionogi & Co Ltd
Sierra Oncology Inc
Sigma-Tau SpA
SignPath Pharma Inc
Simcere Pharmaceutical Group
Sino Biopharmaceutical Ltd
Sotio AS
Spotlight Innovation Inc
Starpharma Holdings Ltd
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
SuviCa Inc
Symphogen A/S
Synactix Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Synermore Biologics Co Ltd
Systimmune Inc
Skip to top


Ask Your Question

Non-Small Cell Lung Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: